Regenacy Pharmaceuticals, LLC
Records under this name other than the patents Regenacy Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Showing 1 to 10 of 10 · Back to Regenacy Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,040,769 | Hdac Inhibitors for the Treatment of Diabetic Peripheral Neuropathy Formerly held Lapsed on the fee record Ended Aug 7, 2026 · High confidence | Lapsed on the fee record | Ended Aug 7, 2026 | High confidence |
| US 9,957,259 | Selective HDAC1 and HDAC2 inhibitors Lapsed on the fee record Ended May 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2026 | From the USPTO record |
| US 9,790,180 | Piperidine Derivatives as HDAC1/2 Inhibitors Lapsed on the fee record Ended Oct 17, 2025 · High confidence | Lapsed on the fee record | Ended Oct 17, 2025 | High confidence |
| US 9,765,066 | Selective HDAC1 and HDAC2 inhibitors Lapsed on the fee record Ended Sep 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 19, 2025 | From the USPTO record |
| US 11,013,740 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy Lapsed on the fee record Ended May 25, 2025 · High confidence | Lapsed on the fee record | Ended May 25, 2025 | High confidence |
| US 10,968,180 | Piperidine Derivatives as HDAC1/2 Inhibitors Lapsed on the fee record Ended Apr 6, 2025 · High confidence | Lapsed on the fee record | Ended Apr 6, 2025 | High confidence |
| US 9,562,013 | Selective HDAC3 inhibitors Lapsed on the fee record Ended Feb 7, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 7, 2025 | From the USPTO record |
| US 10,858,323 | Hdac Inhibitors for the Treatment of Diabetic Peripheral Neuropathy Lapsed on the fee record Ended Dec 8, 2024 · High confidence | Lapsed on the fee record | Ended Dec 8, 2024 | High confidence |
| US 10,774,056 | Substituted piperazines as selective HDAC1,2 inhibitors Lapsed on the fee record Ended Sep 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2024 | From the USPTO record |
| US 9,421,212 | Selective HDAC1 and HDAC2 inhibitors Lapsed on the fee record Ended Aug 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 23, 2024 | From the USPTO record |